Abstract
The close interaction between tumor cells and bone marrow stromal cells plays a crucial role in the tumorigenesis of multiple myeloma (MM). Reelin, an extracellular matrix protein, is found expressed in myeloma cells and is negatively associated with prognosis. We examined the role of Reelin in myeloma cell adhesion to bone marrow stromal cells and the signaling pathways involved. The results revealed that Reelin promoted the adhesion of myeloma cells to HS-5, a bone marrow stromal cell line, via the activation of β1 integrin. The resulting phosphorylation of focal adhesion kinase (FAK) led to the activation of Syk/STAT3 and Akt. Reelin's high affinity receptor ApoER2 indirectly modulated the adhesion of myeloma cells by promoting Reelin expression via Sp1. These findings indicate an important role for Reelin/integrin-β1-induced myeloma cell adhesion to bone marrow stromal cells and highlight the therapeutic potential of targeting Reelin/integrin/FAK axis.
Introduction
Multiple Myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells within the bone marrow. A critical factor in MM progression and treatment failure is "cell adhesion-mediated drug resistance" (CAM-DR). When MM cells adhere to bone marrow stromal cells (BMSCs), they gain protection from chemotherapy-induced apoptosis. While various adhesion molecules have been identified, the complete signaling network remains to be elucidated. This study focuses on Reelin, an extracellular matrix protein primarily known for its role in brain development, which has been found to be overexpressed in MM patients with poor prognosis.
Methods
To investigate the Reelin signaling pathway, researchers utilized human MM cell lines (H929 and U266) and the bone marrow stromal cell line HS-5.
- Molecular Modulation: Reelin was overexpressed using plasmids (pCrl) and silenced using siRNAs targeting Reelin and its receptor, ApoER2.
- Adhesion Assays: MM cells labeled with Calcein-AM were incubated with HS-5 cells. Adhesion was quantified using confocal microscopy.
- Pathway Mapping: Specific inhibitors (e.g., BAY 61-3606 for Syk) and blocking antibodies (CR-50 for Reelin, P4C10 for β1 integrin) were used to delineate the signaling cascade.
- Protein Analysis: Western blotting assessed the phosphorylation of FAK, Syk, STAT3, and Akt.
Results
Reelin Promotes MM Cell Adhesion
The study demonstrated that Reelin acts as a pro-adhesive factor in the bone marrow microenvironment. Overexpression of Reelin significantly enhanced the adhesion of MM cells to HS-5 stromal cells. Conversely, blocking Reelin with the CR-50 antibody or using siRNAs to knock down Reelin expression markedly reduced this adhesion.
Signaling via the β1 Integrin/FAK Axis
Reelin was found to trigger "inside-out" signaling, increasing the affinity of β1 integrin on MM cells for the stromal environment. Reelin treatment resulted in a more than 2-fold increase in activated β1 integrin. This activation leads to a multi-branched signaling cascade: Reelin → β1 integrin → FAK → Syk → STAT3/Akt. Syk was identified as a central node necessary for the activation of both STAT3 and Akt survival pathways.
Indirect Regulation by ApoER2
Interestingly, while ApoER2 is a direct receptor for Reelin in the brain, in MM it appears to regulate Reelin expression indirectly. ApoER2 modulates the transcription factor Sp1, which in turn drives Reelin production. Knocking down ApoER2 led to decreased Reelin levels and subsequent reduction in cell adhesion.
Discussion
This research identifies Reelin as a key mediator of MM cell anchoring within the bone marrow. By hijacking a developmental signaling pathway, MM cells create a protective niche that fosters drug resistance. While these in vitro findings are compelling, future work is needed to validate these mechanisms in 3D models and in vivo. The Reelin/integrin/FAK axis represents a promising therapeutic target; disrupting this "glue" could sensitize MM cells to existing treatments by "unsticking" them from their protective stromal environment.
Summary updated